Albert Bourla: 2025 was a very good year for Pfizer Inc. I'm very pleased with strong execution to deliver and, frankly, overdeliver on our financial commitments. If successful, we will substantially ...
Opportunities lie in Mobile and Point of Care advancements, driven by innovative imaging technologies and promising medical research results. Growth is bolstered by falling costs, creating new ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results